Increased expression of TREM 2 in peripheral cells from mild cognitive impairment patients who progress into Alzheimer's disease
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Background and purpose: Neuroinflammation plays a role in the aetiopathogenesis of Alzheimer's disease (AD). Triggering receptor expressed on myeloid cells 2 (TREM 2), a cell surface receptor of the immunoglobulin superfamily, seems to have protective anti‐inflammatory activity in AD. Methods: Triggering receptor expressed on myeloid cells 2 expression was analysed in peripheral blood mononuclear cells from healthy subjects (CT) and from patients with either AD or mild cognitive impairment (MCI). MCI patients were re‐evaluated at a 2‐year follow‐up to investigate their progression to AD (MCI‐AD) or lack thereof (MCI‐MCI). Results: Triggering receptor expressed on myeloid cells 2 gene expression was higher in AD than CT patients, but was highest in MCI. At recruitment TREM 2 levels were higher in MCI‐AD than in MCI‐MCI, and in MCI‐AD were higher initially than at follow‐up. TREM 2 displayed a moderate degree of sensitivity and specificity for identifying MCI‐AD in all MCI patients. Our data showed higher TREM 2 levels in allele ε4 of apolipoprotein E (ApoE ε4) carriers than non‐carriers in MCI and particularly in MCI‐AD. Conclusions: These data seem to confirm the protective role of TREM 2 in the pre‐clinical stage of AD. Upregulation of TREM 2 in MCI‐AD could be a mechanism to counteract the activation of neuroinflammatory processes. It is possible that TREM 2 and ApoE ε4 interact synergistically in the pre‐clinical stage of AD. Therefore, TREM 2 may be useful as an early peripheral biomarker for the development of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mild cognitive impairment: a concept in evolution
Petersen, R. C., Caracciolo, B., Brayne, C., Gauthier, S., Jelic, V., & Fratiglioni, L. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12190 · Cited by 1,694
Innate immune activation in neurodegenerative disease
Heneka, M. T., Kummer, M. P., & Latz, E. (2014) · Nature Reviews Immunology · doi:10.1038/nri3705 · Cited by 1,437 · cited 1×
“Neuroinflammation is a common feature of neurodegenerative diseases [12].”
BackgroundClassification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
Ray, S., Britschgi, M., Herbert, C., Takeda-Uchimura, Y., Boxer, A., Blennow, K., Friedman, L. F., Galasko, D. R., Jutel, M., Karydas, A., et al. (2007) · Nature Medicine · doi:10.1038/nm1653 · Cited by 1,048 · cited 1×
“There is increasing evidence that inflammation plays a role in brain changes that precede AD, and several studies show an alteration of pro-inflammatory cytokines in the brains of mild cognitive impairment (MCI) patients [15].”
BackgroundAPOE and Alzheimer disease: a major gene with semi-dominant inheritance
Genin, E., Hannequin, D., Wallon, D., Sleegers, K., Hiltunen, M., Combarros, O., Bullido, M. J., Engelborghs, S., De Deyn, P., Berr, C., et al. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.52 · Cited by 714 · cited 1×
“This variant has an odds ratio comparable to allele e4 of apolipoprotein E (ApoE) [18], which is the most common risk factor for both late- and early-onset AD [19].”
BackgroundSelf-citationApolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2)
Atagi, Y., Liu, C.-C., Painter, M. M., Chen, X.-F., Verbeeck, C., Zheng, H., Li, X., Rademakers, R., Kang, S. S., Xu, H., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.679043 · Cited by 587 · cited 1×
“An interaction between TREM2 and ApoE in vitro has been described [20], suggesting that ApoE may act as a ligand to stimulate microglial function through TREM2 [21].”
BackgroundSuárez‐Calvet, M., Kleinberger, G., Araque Caballero, M. Á., Brendel, M., Rominger, A., Alcolea, D., Fortea, J., Lleó, A., Blesa, R., Gispert, J. D., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506123 · Cited by 522 · cited 1×
“A significant increase of CSF sTREM2 levels has been described in the early symptomatic phase of AD [36] and in mild dementia [37].”
BackgroundBouchon, A., Hernández-Munain, C., Cella, M., & Colonna, M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.8.1111 · Cited by 460
Hamerman, J. A., Jarjoura, J. R., Humphrey, M. B., Nakamura, M. C., Seaman, W. E., & Lanier, L. L. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.4.2051 · Cited by 440 · cited 1×
“Several studies have provided evidence suggesting that TREM2 plays a protective role in AD, inhibiting the inflammatory response, enhancing phagocytosis of apoptotic neurons [22] and promoting microglial functions in response to amyloid-b (Ab) deposition [1].”
BackgroundTREM2 variants: new keys to decipher Alzheimer disease pathogenesis
Colonna, M., & Wang, Y. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.7 · Cited by 418
Kawabori, M., Kacimi, R., Kauppinen, T., Calosing, C., Kim, J. Y., Hsieh, C. L., Nakamura, M. C., & Yenari, M. A. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.2620-14.2015 · Cited by 375
Cited by
New insights into the role of TREM2 in Alzheimer’s disease
Gratuze, M., Leyns, C. E. G., & Holtzman, D. M. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0298-9 · Cited by 489
TREM2, microglia, and Alzheimer’s disease.
Qin, Q., Teng, Z., Liu, C., Li, Q., Yin, Y., & Tang, Y. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111438 · Cited by 219
Biomarkers used in Alzheimer’s disease diagnosis, treatment, and prevention
Mahaman, Y. A. R., Embaye, K. S., Huang, F., Li, L., Zhu, F., Wang, J.-Z., Liu, R., Feng, J., & Wang, X. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101544 · Cited by 149
TREM2 ectodomain and its soluble form in Alzheimer’s disease
Yang, J., Fu, Z., Zhang, X., Xiong, M., Meng, L., & Zhang, Z. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01878-2 · Cited by 113
“Several studies have reported the sTREM2 level in the peripheral blood to be higher in AD patients than that in healthy individuals [47, 48], whereas other investigators reported no significant difference [24, 46].”
ResultLista, S., Imbimbo, B. P., Grasso, M., Fidilio, A., Emanuele, E., Minoretti, P., López-Ortiz, S., Martín-Hernández, J., Gabelle, A., Caruso, G., et al. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03163-y · Cited by 81
“In a longitudinal study involving 57 individuals with MCI, higher plasma TREM2 levels and mRNA expression were detected in peripheral blood mononuclear cells (PBMCs) of APOE ε4 positive individuals who later developed AD during the two-year follow-up period [82].”
BackgroundTREM2 regulates innate immunity in Alzheimer’s disease
Li, J.-T., & Zhang, Y. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1148-y · Cited by 76
Alzheimer’s Disease: Advances in Drug Development
Piton, M., Hirtz, C., Desmetz, C., Milhau, J., Lajoix, A. D., Bennys, K., Lehmann, S., & Gabelle, A. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180145 · Cited by 60
TREM2 expression and amyloid‐beta phagocytosis in Alzheimer's disease
La Rosa, F., Agostini, S., Piancone, F., Marventano, I., Hernis, A., Fenoglio, C., Galimberti, D., Scarpini, E., Saresella, M., & Clerici, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108626 · Cited by 50
Metadata
- Authors
- Casati, M., Ferri, E., Gussago, C., Mazzola, P., Abbate, C., Bellelli, G., Mari, D., Cesari, M., & Arosio, B.
- Venue
- European Journal of Neurology
- Publisher
- Wiley
- Published
- 2018-03-26
- Volume
- 25
- Issue
- 6
- Pages
- 805-810
- ISSN
- 1351-5101 (ISSN-L)
- 1468-1331
- OpenAlex
- W2789326733
- Cited by
- 66
- References
- 17
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.